Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

BACKGROUND: Certolizumab pegol, a PEGylated tumour necrosis factor (TNF)-inhibitor, improves the clinical signs and symptoms of rheumatoid arthritis (RA) when used in combination with methotrexate or as monotherapy. This study evaluatedthe cost-utility of certolizumab pegol versusTNF-inhibitors plus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cost Eff Resour Alloc
Main Authors: Hidalgo-Vega, Álvaro, Villoro, Renata, Blasco, Juan Antonio, Talavera, Pablo, Ferro, Belén, Purcaru, Oana
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4484891/
https://ncbi.nlm.nih.gov/pubmed/26124700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-015-0037-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados